Evidence map›Paper›PMID 16305055›Full record

Trial reportDiabetes & vascular disease research2004

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.

Inga Thrainsdottir, Klas Malmberg, Arne Olsson, Mark Gutniak, Lars Rydén

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes & vascular disease research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02655770 phase4completedstarted 2016, after this paper: background citation

Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial

Ran2016Enrolled40Registered outcomes4Posted comparisons0ConditionsCardiac MRI, Diabetes Mellitus Type 2, Diastolic Dysfunction, Myocardial PerfusionArmsliraglutide, Placebo
PMID 22246377PMID 1486584PMID 16386668PMID 18071071PMID 20117433PMID 20466848PMID 4835750PMID 7351930PMID 9498536other papers from this trial
Open the trial in the graph
NCT02694575 completednot on this mapstarted 2015, after this paper: background citation

The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes

TypeobservationalSponsorUniversity of LeicesterRan2015 to 2018Enrolled241ConditionsDiabetes Mellitus, Type 2, Cardiovascular Diseases
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015
    Article
  17. Incretin-related drug therapy in heart failure.Current heart failure reports · 2015
    Review
  18. Article
  19. Review
  20. Cardiovascular effects of incretin therapy in diabetes care.Metabolic syndrome and related disorders · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Inga ThrainsdottirDepartment of Cardiology, Karolinska Hospital, Stockholm, Sweden. inga.thrainsdottir@ks.se
Klas Malmberg
Arne Olsson
Mark Gutniak
Lars Rydén
Karolinska University Hospital · SEStockholm South General Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like peptide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function. The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function. There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function. It is concluded that GLP-1 deserves further evaluation in such patients.

Indexed as

Blood GlucoseC-PeptideDiabetes Mellitus, Type 2Echocardiography, DopplerExercise TestGlucagonGlucagon-Like Peptide 1HeartHeart FailureHumansInfusions, ParenteralInjections, SubcutaneousInsulinMaleMyocardial ContractionPilot ProjectsBlood GlucoseC-PeptideGlucagonGlucagon-Like Peptide 1InsulinRecombinant Proteins

Identifiers

PMID16305055
OpenAlexW1983000201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.